The success of Collection Sites national rollout has led to the expansion into New York, with the site expected to be operational by January 6th.
TORONTO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- QuestCap Inc. (“QuestCap”) (NEO:QSC; OTC:COPRF; FRA:34C1) is pleased to announce the launch of an agreement between its wholly owned subsidiary, Collection Sites, LLC and the Town of East Hampton to launch a pop-up COVID-19 testing site at the city’s town hall for an initial term of 6-months. With individual sites currently achieving strong sales with 7-day rolling average of 86 tests per day and average test price exceeding US$95 per test, this one site can add substantively to QuestCap’s top-line revenue.
About the Agreement
Collection Sites will lease space for a mobile testing site at the Town Hall Campus of the Town of East Hampton. In exchange for lease payments, Collection Sites will offer 350 antigen tests per month to residents of East Hampton as directed by the municipality. With a strong location and a town population of over 20,000, this testing site is expected to generate strong sales over the period of operation.
“With New York state limiting mobile testing centres, we are very excited to be able to launch this testing centre in partnership with the Town of East Hampton,” says Mr. Tim Shelburn, President of Collection Sites. “We believe this agreement further validates our operational model and demonstrates the continued need for COVID-19 testing across the U.S. By providing better access to testing and making testing part of our everyday routine, we can help this country flatten the curve.”
The pop-up labs will be managed by Las Vegas based company Collection Sites, LLC and powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. Appointments and payments will be handled through an online portal www.testbeforeyougo.com.
The key to flattening the curve is to increase testing.
The testing centers will offer convenient access to rapid antibody and antigen (pending availability) tests - which take 8-10 minutes to administer and provide results within 24 hours. The sites also offer regular RT-PCR. All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.
For more information about the pop-up lab, the available sites and services visit www.testbeforeyougo.com.
About QuestCap Inc.
QuestCap Inc. (NEO:QSC; OTC:COPRF; FRA:34C1) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, QuestCap offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.
QuestCap has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.
QuestCap’s primary focus is the sale of COVID-19 IgG/IgM antibody tests authorized by FDA under an EUA for use by authorized laboratories. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.
For additional information, please contact:
Doug Sommerville, CEO
Doug.Sommerville@questcapinc.com
+1 416-301-5418
For investing inquiries please contact:
Evan Veryard
Evan.veryard@questcapinc.com
For US media enquires please contact:
Veronica Welch
veronica@vewprmedia.com
+1-508-643-8000
Cautionary Note Regarding Forward-looking Information
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the agreement among Collection Sites LLC and the Town of East Hampton; the proposed roll-out of testing sites; projected timelines for testing results; projected revenues from the testing; the pursuit by QuestCap of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.